Affordable Access

Access to the full text

Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies

Authors
  • Gewehr, Mayara C. F.
  • Silverio, Renata
  • Rosa-Neto, José Cesar
  • Lira, Fabio S.
  • Reckziegel, Patrícia
  • Ferro, Emer S.
Type
Published Article
Journal
Molecules
Publisher
MDPI AG
Publication Date
Feb 29, 2020
Volume
25
Issue
5
Identifiers
DOI: 10.3390/molecules25051093
PMID: 32121443
PMCID: PMC7179135
Source
PubMed Central
Keywords
License
Green

Abstract

Overweight and obesity are among the most prominent health problems in the modern world, mostly because they are either associated with or increase the risk of other diseases such as type 2 diabetes, hypertension, and/or cancer. Most professional organizations define overweight and obesity according to individual body–mass index (BMI, weight in kilograms divided by height squared in meters). Overweight is defined as individuals with BMI from 25 to 29, and obesity as individuals with BMI ≥30. Obesity is the result of genetic, behavioral, environmental, physiological, social, and cultural factors that result in energy imbalance and promote excessive fat deposition. Despite all the knowledge concerning the pathophysiology of obesity, which is considered a disease, none of the existing treatments alone or in combination can normalize blood glucose concentration and prevent debilitating complications from obesity. This review discusses some new perspectives for overweight and obesity treatments, including the use of the new orally active cannabinoid peptide Pep19, the advantage of which is the absence of undesired central nervous system effects usually experienced with other cannabinoids.

Report this publication

Statistics

Seen <100 times